A new statistical analysis of patients with follicular lymphoma, made possible by 15 years of follow-up data from a SWOG and ...

Cure rate of 42% estimated in cure modeling; highest rate seen for patients with low Follicular Lymphoma International Prognostic Index scores.

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

Unlike some other forms of lymphoma, advanced stage follicular lymphoma is considered incurable. But a new analysis of long-term data on patients treated for the disease years ago with standard ...

Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma. Among patients with relapsed/refractory diffuse large B-cell ...

Personalized treatment strategies have significantly advanced the management of lung cancer brain metastases, improving patient outcomes. Integration of targeted therapies and immunotherapies offers ...

We retrospectively analyzed clinicopathologic data of 98 patients with MCL treated at our center in the past 10 years. STATA 13.0 was used for overall survival (OS) and event-free survival (EFS) ...

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda The cohort included 103 patients (63.1% female, 36.9% ...

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...

NICE recommends epcoritamab for relapsed follicular lymphoma, offering a new option after multiple lines of therapy.